Morton Coleman - AV Therapeutics Vice President
President
Dr. Morton Coleman, M.D., is Vice President of the Company. Dr. Coleman is Clinical Professor of Medicine at the Weill Medical College of Cornell University and the Director of the Center for Lymphoma and Myeloma at the New York Presbyterian HospitalWeill Cornell Campus, a position he has held since 1997. Dr. Colemans expertise is in the treatment of lymphoma, myeloma, Waldenstroms macroglobulinemia, and associated diseases. He has played an instrumental role in devising the standard treatment for Hodgkins disease, the use of infusional chemotherapy in lymphoma, the concept of dose intensity and its use in myeloma and lymphoma, the combined use of thalidomide in myeloma, the role of PET scanning in lymphoma, the innovative applications of monoclonal antibodies in lymphoma and many other developments. Dr. Coleman is chairman of the Medical Affiliate Board of Lymphoma Research Foundation and is on its Board of Directors and Scientific Review committee. He is also a member of the scientific review committees of the International Waldenstroms Foundation and the Research Fund for Waldenstroms, Ltd since 2013.
| Age | 71 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Phone | 410-507-1365 |
| Web | http://www.avth.net |
AV Therapeutics Management Efficiency
The company has return on total asset (ROA) of (317.24) % which means that it has lost $317.24 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (333.8) %, meaning that it created substantial loss on money invested by shareholders. AV Therapeutics' management efficiency ratios could be used to measure how well AV Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 294.7 K in liabilities. AV Therapeutics has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist AV Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, AV Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AV Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AVTH to invest in growth at high rates of return. When we think about AV Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Andrew Blanchard | Teradyne | N/A | |
| James Klein | Qorvo Inc | 52 | |
| Thomas Wessel | Analog Devices | 47 | |
| Sanjay Mehta | Teradyne | 55 | |
| Walter Vahey | Teradyne | 59 | |
| Manish Bhatia | Micron Technology | 52 | |
| Ryan Driscoll | Teradyne | N/A | |
| Kim Povlsen | Teradyne | N/A | |
| Patrick Otte | Micron Technology | 49 | |
| Chitung Liu | United Microelectronics | 58 | |
| Steven Pietkiewicz | Analog Devices | 58 | |
| Ernie Maddock | Micron Technology | 56 | |
| Jeff VerHeul | Micron Technology | N/A | |
| Robert Peglar | Micron Technology | N/A | |
| Jean Philibert | Analog Devices | 56 | |
| Bradford BSEE | Teradyne | 65 | |
| Michael Bokan | Micron Technology | 62 | |
| Jianping Li | Jutal Offshore Oil | 44 | |
| Rugang He | Jutal Offshore Oil | 51 | |
| Richard Burns | Teradyne | 60 | |
| Steven Creviston | Qorvo Inc | 60 | |
Management Performance
| Return On Equity | -333.8 | |||
| Return On Asset | -317.24 |
AV Therapeutics Leadership Team
Elected by the shareholders, the AV Therapeutics' board of directors comprises two types of representatives: AV Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AVTH. The board's role is to monitor AV Therapeutics' management team and ensure that shareholders' interests are well served. AV Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AV Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Debabrata Banerjee, Clinical Development Officer | ||
| Raj Tiwari, Chairman of Science Board, Chief Scientific Officer and Director | ||
| Robert Pollock, COO | ||
| Robert Gardner, Director | ||
| Abraham Mittelman, Chairman of the Board, CEO, CFO | ||
| Morton Coleman, Vice President | ||
| Jan Geliebter, Secretary |
AVTH Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is AV Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -333.8 | |||
| Return On Asset | -317.24 | |||
| Current Valuation | 430.89 K | |||
| Shares Outstanding | 81.88 M | |||
| Price To Earning | (0.47) X | |||
| EBITDA | (1.64 M) | |||
| Net Income | (776.15 K) | |||
| Cash And Equivalents | 273.22 K | |||
| Total Debt | 294.7 K | |||
| Current Ratio | 0.31 X |
Pair Trading with AV Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AV Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AV Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Chubb could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Chubb when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Chubb - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Chubb to buy it.
The correlation of Chubb is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Chubb moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Chubb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Chubb can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in AVTH Pink Sheet
If you are still planning to invest in AV Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AV Therapeutics' history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities |